Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Macrophage Colony-Stimulating Factor
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Macrophage Colony-Stimulating Factor

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A mononuclear phagocyte colony-stimulating factor (m-csf) synthesized by mesenchymal cells.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (907 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A mononuclear phagocyte colony-stimulating factor (m-csf) synthesized by mesenchymal cells. The compound stimulates the survival, proliferation, and differentiation of hematopoietic cells of the monocyte-macrophage series. m-csf is a disulfide-bonded glycoprotein dimer with a MW of 70 kDa. It binds to a specific high affinity receptor (receptor, macrophage colony-stimulating factor).

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Colony-Stimulating Factor 1; Colony Stimulating Factor 1; CSF-1; CSF-M; M-CSF; Colony-Stimulating Factor, Macrophage; Colony Stimulating Factor, Macrophage.

Where it fits in the MeSH classification

Broader topics
Colony-Stimulating Factors
See also
Receptor, Macrophage Colony-Stimulating Factor

Related concepts

  • M-Csf
  • Receptor
  • Macrophage Colony-Stimulating Factor

Research landscape

PubMed indexes 5,150 records tagged with the MeSH heading “Macrophage Colony-Stimulating Factor” (counts retrieved 2026-10-31). 618 of them (12.0%) were published from 2020 onward, and the busiest period so far is through 1999 with 1,857 records.

Reviews account for 393 records (7.6%) and meta-analyses for 4. Randomized controlled trials number 32 (0.6%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 1,857 records; 2000-2009: 1,412 records; 2010-2019: 1,263 records; 2020 onward: 618 records1,857through 19991,4122000-20091,2632010-20196182020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19991,857
2000-20091,412
2010-20191,263
2020 onward618
Share of records by publication typeReviews: 7.6 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 0.6 percentReviews7.6% (393)Meta-analyses0.1% (4)Randomized controlled trials0.6% (32)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 5,150 PubMed records
TypeRecordsShare
Reviews3937.6%
Meta-analyses40.1%
Randomized controlled trials320.6%

Method: PubMed query "Macrophage Colony-Stimulating Factor"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma
Zhang A, Qian Y, Ye Z, Chen H, Xie H, Zhou L, et al.
2017Research article
Design not recorded in structured metadata
188cc by
PMID 28097809 · DOI · PMC5313646
Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer
Lin W, Xu D, Austin CD, Caplazi P, Senger K, Sun Y, et al.
2019Research article
Design not recorded in structured metadata
163cc by
PMID 31552020 · DOI · PMC6736990
Microglia polarization in nociplastic pain: mechanisms and perspectives
Atta AA, Ibrahim WW, Mohamed AF, Abdelkader NF
2023Review article
Design not recorded in structured metadata
152cc by
PMID 37069462 · DOI · PMC10229465
Synovial macrophage diversity and activation of M-CSF signaling in post-traumatic osteoarthritis
Knights AJ, Farrell EC, Ellis OM, Song MJ, Appleton CT, Maerz T
2025Research article
Design not recorded in structured metadata
35cc by
PMID 39969512 · DOI · PMC11839164

Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma [1]

Research article Zhang A, Qian Y, Ye Z, Chen H, Xie H, Zhou L, et al. · · 2017 · cited 188 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Pancreatic ductal adenocarcinoma (PDAC) is characterized by remarkable desmoplasia with infiltration of distinct cellular components.
Closing excerpt
Collectively, our data revealed that pancreatic CAFs were able to induce a tumor-promoting TAM phenotype partly through secreted M-CSF and enhanced ROS production in monocytes, indicating possible treatment strategies by targeting stromal cell interaction within PDAC microenvironment.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (202 words)

Pancreatic ductal adenocarcinoma (PDAC) is characterized by remarkable desmoplasia with infiltration of distinct cellular components. Cancer-associated fibroblasts (CAFs) has been shown to be among the most prominent cells and played a significant role in shaping the tumor microenvironment by interacting with other type of cells. Here, we aimed to investigate the effect of CAFs in modulating phenotype of tumor-associated macrophages (TAM). Under treatment of CAFs conditioned medium (CM) or direct co-culture with CAFs, monocytes exhibited enhanced expression of CD206 and CD163 compared with control group (P < 0.01). The induction of M2 polarization was mediated by increased reactive oxygen species (ROS) production in monocytes as ROS elimination abolished the effect of CAFs (P < 0.05). The supernatant analysis showed that pancreatic CAFs produced increased macrophage colony-stimulating factor (M-CSF). Upon treatment of M-CSF neutralizing antibody, the ROS generation and M2 polarization of CAFs CM-stimulated monocytes were significantly inhibited (P < 0.05). In addition, the CAFs-induced M2 macrophages significantly enhanced pancreatic tumor cell growth, migration, and invasion. Collectively, our data revealed that pancreatic CAFs were able to induce a tumor-promoting TAM phenotype partly through secreted M-CSF and enhanced ROS production in monocytes, indicating possible treatment strategies by targeting stromal cell interaction within PDAC microenvironment.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 28097809 · DOI · PMC5313646

Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer [2]

Research article Lin W, Xu D, Austin CD, Caplazi P, Senger K, Sun Y, et al. · · 2019 · cited 163 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Colony-stimulating factor 1 (CSF1) and interleukin 34 (IL34) signal via the CSF1 receptor to regulate macrophage differentiation.
Closing excerpt
Thus, IL34 and CSF1 play non-redundant roles in macrophage differentiation, and therapeutic intervention targeting IL34 and/or CSF1 may provide an effective treatment in macrophage-driven immune-pathologies.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (187 words)

Colony-stimulating factor 1 (CSF1) and interleukin 34 (IL34) signal via the CSF1 receptor to regulate macrophage differentiation. Studies in IL34- or CSF1-deficient mice have revealed that IL34 function is limited to the central nervous system and skin during development. However, the roles of IL34 and CSF1 at homeostasis or in the context of inflammatory diseases or cancer in wild-type mice have not been clarified in vivo. By neutralizing CSF1 and/or IL34 in adult mice, we identified that they play important roles in macrophage differentiation, specifically in steady-state microglia, Langerhans cells, and kidney macrophages. In several inflammatory models, neutralization of both CSF1 and IL34 contributed to maximal disease protection. However, in a myeloid cell-rich tumor model, CSF1 but not IL34 was required for tumor-associated macrophage accumulation and immune homeostasis. Analysis of human inflammatory conditions reveals IL34 upregulation that may account for the protection requirement of IL34 blockade. Furthermore, evaluation of IL34 and CSF1 blockade treatment during Listeria infection reveals no substantial safety concerns. Thus, IL34 and CSF1 play non-redundant roles in macrophage differentiation, and therapeutic intervention targeting IL34 and/or CSF1 may provide an effective treatment in macrophage-driven immune-pathologies.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31552020 · DOI · PMC6736990

Microglia polarization in nociplastic pain: mechanisms and perspectives [3]

Review article Atta AA, Ibrahim WW, Mohamed AF, Abdelkader NF · · 2023 · cited 152 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Nociplastic pain is the third classification of pain as described by the International Association for the Study of Pain (IASP), in addition to the neuropathic and nociceptive pain classes.
Closing excerpt
LPS lipopolysaccharide, TNF-α tumor necrosis factor-α, INF-γ Interferon gamma, ATP adenosine triphosphate, 49 P2Y12/13R purinergic P2Y 12/13 receptor, P2X4/7R purinergic P2X 4/7 receptor, SP Substance P, NK-1R Neurokinin 1 receptor, CCL2 CC motif ligand 2, CCR2 CC motif ligand 2 receptor, CSF-1 colony-stimulating factor 1, CSF-1R colony-stimulating factor 1 receptor, CX3CL1 CX3C motif ligand 1, CX3XR1 CX3C motif ligand 1 receptor, TLR toll-like receptor, MAPK mitogen-activated protein kinases, JNK jun N-terminal kinase, ERK extracellular signal-regulated kinase, iNOS Inducible nitric oxide synthase, IL-1β interleukin-1β, IL-6 interleukin-6, BDNF brain-derived neurotrophic factor, GABA γ-Aminobutyric acid, GABAR γ-Aminobutyric acid receptor, NMDAR N-methyl-D-aspartate receptor, AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazolepropi-onic acid receptor, IL-4 interleukin-4, IL-13 interleukin-13, IL-10 interleukin-10, Arg-1 Arginase 1, FGF fibroblast growth factor, GDNF glial cell-derived neurotrophic factor, IGF-1 insulin-like growth factor-1, NGF nerve growth factor, CD Cluster of differentiation.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (282 words)

Nociplastic pain is the third classification of pain as described by the International Association for the Study of Pain (IASP), in addition to the neuropathic and nociceptive pain classes. The main pathophysiological mechanism for developing nociplastic pain is central sensitization (CS) in which pain amplification and hypersensitivity occur. Fibromyalgia is the prototypical nociplastic pain disorder, characterized by allodynia and hyperalgesia. Much scientific data suggest that classical activation of microglia in the spinal cord mediates neuroinflammation which plays an essential role in developing CS. In this review article, we discuss the impact of microglia activation and M1/M2 polarization on developing neuroinflammation and nociplastic pain, besides the molecular mechanisms engaged in this process. In addition, we mention the impact of microglial modulators on M1/M2 microglial polarization that offers a novel therapeutic alternative for the management of nociplastic pain disorders. Illustrating the mechanisms underlying microglia activation in central sensitization and nociplastic pain. LPS lipopolysaccharide, TNF-α tumor necrosis factor-α, INF-γ Interferon gamma, ATP adenosine triphosphate, 49 P2Y12/13R purinergic P2Y 12/13 receptor, P2X4/7R purinergic P2X 4/7 receptor, SP Substance P, NK-1R Neurokinin 1 receptor, CCL2 CC motif ligand 2, CCR2 CC motif ligand 2 receptor, CSF-1 colony-stimulating factor 1, CSF-1R colony-stimulating factor 1 receptor, CX3CL1 CX3C motif ligand 1, CX3XR1 CX3C motif ligand 1 receptor, TLR toll-like receptor, MAPK mitogen-activated protein kinases, JNK jun N-terminal kinase, ERK extracellular signal-regulated kinase, iNOS Inducible nitric oxide synthase, IL-1β interleukin-1β, IL-6 interleukin-6, BDNF brain-derived neurotrophic factor, GABA γ-Aminobutyric acid, GABAR γ-Aminobutyric acid receptor, NMDAR N-methyl-D-aspartate receptor, AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazolepropi-onic acid receptor, IL-4 interleukin-4, IL-13 interleukin-13, IL-10 interleukin-10, Arg-1 Arginase 1, FGF fibroblast growth factor, GDNF glial cell-derived neurotrophic factor, IGF-1 insulin-like growth factor-1, NGF nerve growth factor, CD Cluster of differentiation.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37069462 · DOI · PMC10229465

Synovial macrophage diversity and activation of M-CSF signaling in post-traumatic osteoarthritis [4]

Research article Knights AJ, Farrell EC, Ellis OM, Song MJ, Appleton CT, Maerz T · · 2025 · cited 35 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Synovium is home to immune and stromal cell types that orchestrate inflammation following a joint injury; in particular, macrophages are central protagonists in this process.
Closing excerpt
Nuanced characterization of the distinct functions, origins, and disease kinetics of macrophage subtypes in PTOA will be critical for targeting these highly versatile cells for therapeutic purposes.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (236 words)

Synovium is home to immune and stromal cell types that orchestrate inflammation following a joint injury; in particular, macrophages are central protagonists in this process. We sought to define the cellular and temporal dynamics of the synovial immune niche in a mouse model of post-traumatic osteoarthritis (PTOA), and to identify stromal-immune crosstalk mechanisms that coordinate macrophage function and phenotype. We induced PTOA in mice using a non-invasive tibial compression model of anterior cruciate ligament rupture (ACLR). Single-cell RNA-sequencing and flow cytometry were used to assess immune cell populations in healthy (Sham) and injured (7 and 28 days post-ACLR) synovium. Characterization of synovial macrophage polarization states was performed, alongside computational modeling of macrophage differentiation, as well as implicated transcriptional regulators and stromal-immune communication axes. Immune cell types are broadly represented in healthy synovium, but experience drastic expansion and speciation in PTOA, most notably in the macrophage portion. We identified several polarization states of macrophages in synovium following joint injury, underpinned by distinct transcriptomic signatures, and regulated in part by stromal-derived macrophage colony-stimulating factor signaling. The transcription factors Pu.1, Cebpα, Cebpβ, and Jun were predicted to control differentiation of systemically derived monocytes into pro-inflammatory synovial macrophages. In summary, we defined different synovial macrophage subpopulations present in healthy and injured mouse synovium. Nuanced characterization of the distinct functions, origins, and disease kinetics of macrophage subtypes in PTOA will be critical for targeting these highly versatile cells for therapeutic purposes.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39969512 · DOI · PMC11839164

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article CSF-1 regulation of the wandering macrophage: complexity in action [5]
    Pixley FJ, Stanley ER · Trends Cell Biol · 2004 · cited 643 times (Europe PMC)
  • Research article Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling [6]
    Hume DA, MacDonald KP · Blood · 2012 · cited 626 times (Europe PMC)
  • Research article Colony-stimulating factor-1 in immunity and inflammation [7]
    Chitu V, Stanley ER · Curr Opin Immunol · 2006 · cited 507 times (Europe PMC)
  • Research article Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage [8]
    Ushach I, Zlotnik A · J Leukoc Biol · 2016 · cited 463 times (Europe PMC)
  • Research article Biology and action of colony--stimulating factor-1 [9]
    Stanley ER, Berg KL, Einstein DB, Lee PS, Pixley FJ, Wang Y, et al. · Mol Reprod Dev · 1997 · cited 325 times (Europe PMC)
  • Research article Emerging Roles for CSF-1 Receptor and its Ligands in the Nervous System [10]
    Chitu V, Gokhan Ş, Nandi S, Mehler MF, Stanley ER · Trends Neurosci · 2016 · cited 310 times (Europe PMC)

References

  1. Zhang A, Qian Y, Ye Z, Chen H, Xie H, Zhou L, et al.. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. . 2017. PMID 28097809 · DOI · PMC5313646
  2. Lin W, Xu D, Austin CD, Caplazi P, Senger K, Sun Y, et al.. Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer. . 2019. PMID 31552020 · DOI · PMC6736990
  3. Atta AA, Ibrahim WW, Mohamed AF, Abdelkader NF. Microglia polarization in nociplastic pain: mechanisms and perspectives. . 2023. PMID 37069462 · DOI · PMC10229465
  4. Knights AJ, Farrell EC, Ellis OM, Song MJ, Appleton CT, Maerz T. Synovial macrophage diversity and activation of M-CSF signaling in post-traumatic osteoarthritis. . 2025. PMID 39969512 · DOI · PMC11839164
  5. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 2004. PMID 15519852 · DOI
  6. Hume DA, MacDonald KP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012. PMID 22186992 · DOI
  7. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol. 2006. PMID 16337366 · DOI
  8. Ushach I, Zlotnik A. Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage. J Leukoc Biol. 2016. PMID 27354413 · DOI · PMC4982611
  9. Stanley ER, Berg KL, Einstein DB, Lee PS, Pixley FJ, Wang Y, et al.. Biology and action of colony--stimulating factor-1. Mol Reprod Dev. 1997. PMID 8981357 · DOI
  10. Chitu V, Gokhan Ş, Nandi S, Mehler MF, Stanley ER. Emerging Roles for CSF-1 Receptor and its Ligands in the Nervous System. Trends Neurosci. 2016. PMID 27083478 · DOI · PMC4884457

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Granulocyte Colony-Stimulating FactorDrugs and Chemicals
  • Granulocyte-Macrophage Colony-Stimulating FactorDrugs and Chemicals
  • Colony-Stimulating FactorsDrugs and Chemicals
  • FilgrastimDrugs and Chemicals
  • ThrombopoietinDrugs and Chemicals
  • CD40 LigandDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

5,150
PubMed records on this heading
12%
published since 2020
393
review articles
32
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Granulocyte Colony-Stimulating FactorDrugs and Chemicals
  • Granulocyte-Macrophage Colony-Stimulating FactorDrugs and Chemicals
  • Colony-Stimulating FactorsDrugs and Chemicals
  • FilgrastimDrugs and Chemicals
  • ThrombopoietinDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support